Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Daniel M. Freed"'
Autor:
Santosh Kesari, Feng Wang, Tiffany Juarez, Shashaanka Ashili, C. Pawan K. Patro, Jose Carrillo, Minhdan Nguyen, Judy Truong, Joan Levy, Josh Sommer, Daniel M. Freed, Joanne Xiu, Yuki Takasumi, Eric Bouffet, Jaya M. Gill
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-14 (2023)
Abstract Chordomas are rare slow growing tumors, arising from embryonic remnants of notochord with a close predilection for the axial skeleton. Recurrence is common and no effective standard medical therapy exists. Thymidylate synthase (TS), an intra
Externí odkaz:
https://doaj.org/article/9a4de9015fe54642aeca5eb33d0c41b7
Autor:
Tanaz Sharifnia, Mathias J. Wawer, Amy Goodale, Yenarae Lee, Mariya Kazachkova, Joshua M. Dempster, Sandrine Muller, Joan Levy, Daniel M. Freed, Josh Sommer, Jérémie Kalfon, Francisca Vazquez, William C. Hahn, David E. Root, Paul A. Clemons, Stuart L. Schreiber
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-17 (2023)
Cancer cells possess unique molecular features that can confer an increased dependence on specific genes. Here, the authors use CRISPR-Cas9 screens to identify selectively essential genes and therapeutic targets in chordoma.
Externí odkaz:
https://doaj.org/article/15d1d503cc354ceb925abcc12163767f
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
The development of effective and personalized treatment options for patients with rare cancers like chordoma is hampered by numerous challenges. Biomarker-guided repurposing of therapies approved in other indications remains the fastest path to redef
Externí odkaz:
https://doaj.org/article/629525a0c420446492929d759b48c284
Autor:
Tanaz Sharifnia, Mathias J. Wawer, Amy Goodale, Yenarae Lee, Mariya Kazachkova, Joshua M. Dempster, Sandrine Muller, Joan Levy, Daniel M. Freed, Josh Sommer, Jérémie Kalfon, Francisca Vazquez, William C. Hahn, David E. Root, Paul A. Clemons, Stuart L. Schreiber
Identifying the spectrum of genes required for cancer cell survival can reveal essential cancer circuitry and therapeutic targets, but such a map remains incomplete for many cancer types. We apply genome-scale CRISPR-Cas9 loss-of-function screens to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::791e63be849b8a481155c9ad9335294a
https://doi.org/10.1101/2022.08.17.504193
https://doi.org/10.1101/2022.08.17.504193
Publikováno v:
Cancer Research. 83:6195-6195
Chordoma is a rare bone cancer with a high rate of disease recurrence and no approved systemic therapies. Tumor profiling studies indicate a significant number of chordomas are characterized by alterations in SWI/SNF chromatin remodeling and DNA dama
Publikováno v:
Cancer Research. 83:4865-4865
Target discovery studies have identified EGFR inhibition as a promising therapeutic strategy in chordoma, motivating ongoing clinical trials. Yet EGFR is not mutated in chordoma, leaving the mechanisms associated with EGFR inhibitor (EGFRi) sensitivi
Autor:
Melinda A. Day, Douglas C. Saffran, Tressa Hood, Nikolaus Obholzer, Akanksha Pandey, Charles Y. Lin, Pavan Kumar, Daniel M. Freed, Jorge DiMartino
Publikováno v:
Cancer Research. 82:2564-2564
Lineage-specific transcriptional networks drive cellular differentiation and development. Disruption of these specific cell programs can result in cancer and create a subset of tumors that are “transcriptionally addicted.” Sarcomas, for example,
Autor:
Jeff Testerman, Daniel M. Freed
When Lt. Commander Bobby Thompson surfaced in Tampa in 1998, it was as if he had fallen from the sky, providing no hint of his past life. Eleven years later, St. Petersburg Times investigative reporter Jeff Testerman visited the rundown duplex Thomps
Publikováno v:
Cell. 164:1172-1184
Cell signaling is dominated by analyzing positive responses to stimuli. Signal activation is balanced by negative regulators that are generally considered to terminate signaling. Rather than exerting only negative effects, however, many such regulato